Immune reconstitution following rituximab-based immunochemotherapy in pediatric patients with B-cell non-Hodgkin lymphomas

Leuk Lymphoma. 2022 Jan;63(1):217-221. doi: 10.1080/10428194.2021.1998486. Epub 2021 Nov 2.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Child
  • Humans
  • Immune Reconstitution*
  • Immunotherapy
  • Lymphoma, B-Cell* / drug therapy
  • Rituximab / therapeutic use

Substances

  • Rituximab